Skip to content

Search

The Kids respiratory researcher wins prestigious prize at 2021 Premier’s Science Awards

The Kids Research Institute Australia researcher, Niamh Troy, has been named a joint winner of the Exxon Mobile Student Scientist of the Year award at the Premier’s Science Awards.

Enhancing the lung health for preterm birth survivors by uncovering treatable traits

A project to uncover treatable traits to improve the lung health of people born preterm has been made possible thanks to a $1.99 million Medical Research Future Fund (MRFF) grant. 

Community partnership sets priorities for preterm lung health research

Respiratory disease remains one of the most significant complications of preterm birth, with lasting consequences.

Reducing the asthma burden: generous grant secured to develop world-first treatment

Researchers developing a world-first treatment that targets an underlying cause of asthma have secured a $499,640 grant from the Future Health, Research and Innovation Fund – Innovation Seed Fund.

Chronic Lung Disease of Prematurity

Each year, 11% (15 million) of the world’s babies are delivered before 37 weeks’ gestation.

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

Healthy Lungs & Immune Development

Focusing on the developmental trajectories of respiratory health includes developing strategies to improve and support immune system function and development over the life course.

Multi-million-dollar investment in child health to support vital research

Four The Kids Research Institute Australia researchers have received prestigious fellowships and four significant cohort studies led or co-led by The Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund.

Major grant supports innovative infant lung health study

A ground-breaking global clinical trial to improve the lifelong lung health of children born extremely prematurely has been awarded a Medical Research Future Fund (MRFF) International Clinical Trials Collaborations Grant totalling almost $3 million.

Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease

Mycobacteroides abscessus (MABS) is within the non-tuberculous mycobacteria family. It inhabits soil and water, exhibits multi-antibiotic resistance and causes opportunistic lung infections, which may progress to symptomatic MABS-pulmonary disease (MABS-PD) associated with substantial morbidity, increased healthcare utilisation, impaired quality of life and increased mortality.